Geneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

BARCELONA -- An investigational opioid agonist/antagonist reduced chronic cough frequency in patients with idiopathic pulmonary fibrosis (IPF), interim findings from a small randomized study showed.

Chronic cough affects some 80% of patients with idiopathic pulmonary fibrosis (IPF) and most patients consider it to be one of the most distressing IPF symptoms. In an early phase trial, the ...

Please provide your email address to receive an email when new articles are posted on . Between baseline and week 6, the number of coughs per hour significantly fell among those receiving extended ...